替吉奥联合伽马刀治疗食管癌腹膜后淋巴结转移的临床观察

葛宁; 詹必红; 常娜; 臧春宝

留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

替吉奥联合伽马刀治疗食管癌腹膜后淋巴结转移的临床观察

葛宁 , 詹必红 , 常娜 , 臧春宝

文章导航 > 蚌埠医学院学报 > 2015, 40 > 10: (1346-1349)

引用本文:

Citation:

替吉奥联合伽马刀治疗食管癌腹膜后淋巴结转移的临床观察

安徽省肿瘤医院放疗科, 安徽合肥 230031

作者简介: 葛宁(1981-),男,硕士,住院医师.

中图分类号: R735.1

The clinical observation of the tegafur combined with body gamma knife in the treatment of esophageal neoplasm complicated with retroperitoneal lymph node metastasis

Department of Radiotherapy, Anhui Provincial Cancer Hospital, Hefei Anhui 230031, China
CLC number: R735.1

摘要: 目的: 探讨替吉奥(S1)联合体部伽马刀治疗食管癌腹膜后淋巴结转移的疗效及不良反应。方法: 回顾性分析69例食管癌腹膜后淋巴结转移患者临床资料, 体部伽马刀治疗时用真空垫和三维立体定向体架固定, 增强CT扫描, 肿瘤靶区外扩10 mm为计划靶区, 50%等剂量线包绕95%计划靶区为处方剂量线, 每次350～450 cGy, 5次/周。10～12次完成。肿瘤边缘总剂量:4 200～4 950 cGy。69例中联合组36例, 行体部伽马刀治疗联合口服S1 40 mg/m²,2次/天, 口服21 d, 28 d为1个周期, 口服4个周期;对照组33例, 单纯行体部伽马刀治疗。结果: 联合组近期总有效率和1年生存率分别为86.11%、77.78%, 对照组分别为63.63%、54.54%, 联合组1年生存率高于对照组(P<0.05)。联合组疼痛缓解总有效率为91.18%, 对照组77.42%, 差异无统计学意义(P>0.05)。2组患者治疗过程中的急性不良反应差异均无统计学意义(P>0.05), 患者均可耐受, 经积极治疗可好转, 未发生治疗相关性病死亡。结论: S1联合体部伽马刀治疗食管癌腹膜后淋巴结转移可提高1年生存率, 不良反应无明显增加。
- 食管肿瘤 /
- 腹膜后转移瘤 /
- 替吉奥 /
- 伽马刀
Abstract: Objective: To evaluate the effects and adverse reactions of the tegafur combined with body gamma knife in the treatment of patients with esophageal neoplasm complicated with retroperitoneal lymph node metastasis.Methods: The clinical data of 69 esophageal neoplasm patients with retroperitoneal lymph node metastases were retrospectively analyzed.Fixing vacuum pad and three-dimensional stereotactic body,enhancing CT scan,enlarging the tumor target area for 10 mm as planning target area,50% dose line embracing 95% planning target area as prescription dose curve and 350 to 450 cGy one time(5 times a week) were implemented at the time of body gamma knife therapy.The treatment was consist of 10 to 12 times,and the total dose of the tumor margin was 4 200-4 950 cGy.Among 69 cases,36 patients(combination group) were treated with the body gamma knife combined with tegafur(40 mg/m²,2 times 1 d,28 days 1 cycle for 4 cycles),33 patients(control group) were only treated with the body gamma knife therapy.Results: The short-term effective rate and 1-year survival rate in the combination group and control group were 86.11% & 77.78% and 63.63% & 54.54%,respectively.The 1-year survival rate in the combination group was higher than that in the control group(P<0.05).The total effective rate of pain relief in the combination group and control group were 91.18% and 77.42%,respectively,the difference of which was not statistically significant(P>0.05).The difference of the acute adverse reaction between two groups was not statistically significant(P>0.05).The patients could tolerate,and were improved after positive treatment.No case died.Conclusions: The treatment of patients with esophageal neoplasm complicated with retroperitoneal lymph node metastasis with tegafur combined with body gamma knife treatment can improve 1-year survival rate,and does not increase the adverse reaction of patients.
- esophageal neoplasms /
- retroperitoneal lymph node metastasis /
- tegafur /
- gamma knife therapy

[1]	Janunger KG,Hafstrm L,Glimedius B.Chemotherapy in gastric cancer:a review and updated meta-analysis[J].Eur J Surg,2002, 168 (11):597-608
[2]	Wong R,Malthaner R.Combined chemotherapy and radiotherapy (without surgery) compared with radiotherapy alone in localized carcinoma of the esophagus[J].Cochrane Database Syst Rev,2006(1):CD002092.
[3]	夏廷毅.SBRT临床应用结果的思考[J].医疗装备, 2009, 22 (7):1-4.
[4]	Zeng L,Ou G,Itasaka S, et al.TS-1 enhances the effect of radiotherapy by suppressing radiation-induced hypoxia-inducible factor-1 activation and inducing endothelial cell apoptosis[J].Cancer Sci,2008, 99 (11):2327-2335.
[5]	Ozaway Y,iuni N,Naitoh T,et al.Phase Ⅱ study of combination chemotherapy with S-1 and weekly cisplatin in patients with previously untreated advanced non-small cell lung cancer[J].Lung Cancer,2009,63(1):68-71.
[6]	孙瑶, 冯保同, 张士义, 等.替吉奥胶囊对食管癌适形放疗增敏作用的临床观察[J].中华肿瘤防治杂志, 2012, 19 (18):1410-1412.
[7]	周诚忠, 华海燕, 夏海波, 等.立体定向适形放射治疗腹膜后转移癌 30 例近期疗效分析[J].东南国防医药,2007, 9 (3):216-217.[8] 任朝英, 贾漪涛, 赵武杰, 等.体部伽玛刀治疗腹膜后淋巴结转移癌92例近期疗效观察[J].河北医科大学学报, 2011, 32 (12):1463-1464.
[8]	于金明, 谢印法, 于甬华, 等.立体定向放射结合介入治疗腹膜后转移癌[J].中华放射肿瘤学杂志, 2001, 10 (1):60-61.
[9]	张新良, 王晓萍, 丁巍, 等.消化道肿瘤腹腔淋巴结转移3D-CRT治疗的临床观察[J].中华肿瘤防治杂志, 2011, 18 (13):1039-1042.

[1]	周燕 , 汪庚明 , 何泽来 , 张亚军 , 李红伟 , 景奇骏 . 替吉奥同步化疗联合放疗治疗老年食管癌的临床疗效分析. 蚌埠医学院学报, 2020, 45(7): 871-875. doi: 10.13898/j.cnki.issn.1000-2020.07.008
[2]	杨武 , 喻永龙 , 朱西平 , 张振华 . 替吉奥和卡培他滨分别联合奥沙利铂化疗对晚期胃癌疗效观察. 蚌埠医学院学报, 2014, 39(11): 1512-1514.
[3]	何广思 , 蒋宗惠 , 章敢 . 替吉奥单药与XELOX方案一线治疗老年晚期胃癌的疗效比较. 蚌埠医学院学报, 2017, 42(2): 185-188. doi: 10.13898/j.cnki.issn.1000-2200.2017.02.015
[4]	郑中显 , 潘明 . 阿帕替尼联合替吉奥用于初始治疗失败后晚期肝癌的疗效及安全性分析. 蚌埠医学院学报, 2020, 45(7): 917-920. doi: 10.13898/j.cnki.issn.1000-2020.07.020
[5]	于东红 , 周蕾 , 郭冰沁 , 承泽农 , 王萍 . MMP-2、Ki67在食管癌中的表达及与肿瘤增殖、转移的关系. 蚌埠医学院学报, 2005, 30(5): 383-385.
[6]	朱小康 , 朱自江 , 陈学忠 , 薛继军 , 郑凤长 , 汪淑芸 . 整合素3和Ki-67在食管鳞状细胞癌中的表达及其与术后复发转移和预后的关系. 蚌埠医学院学报, 2012, 36(10): 1193-1997.
[7]	熊海科 , 朱自江 , 陈学忠 , 薛继军 , 朱小康 , 赵海龙 , 郑凤长 . MMP-9、TIMP-2在食管鳞状细胞癌的表达及与术后复发转移和预后的关系. 蚌埠医学院学报, 2014, 39(7): 879-883.
[8]	卫军 , 马宜传 . 能谱CT成像定性评估不同分化食管癌转移淋巴结的应用价值. 蚌埠医学院学报, 2021, 46(1): 25-28, 32. doi: 10.13898/j.cnki.issn.1000-2200.2021.01.007
[9]	吴江涛 . 表浅型食管癌淋巴结转移相关危险因素分析及其临床意义. 蚌埠医学院学报, 2021, 46(4): 525-527. doi: 10.13898/j.cnki.issn.1000-2200.2021.04.025
[10]	赵莉 , 侯滨芬 , 邓敏 . T1b期食管鳞癌淋巴结转移及预后危险因素分析. 蚌埠医学院学报, 2022, 47(4): 469-472. doi: 10.13898/j.cnki.issn.1000-2200.2022.04.011
[11]	单宏杰 , 马骖 . 整合化疗治疗老年局部晚期胃癌的临床研究. 蚌埠医学院学报, 2020, 45(3): 348-350, 354. doi: 10.13898/j.cnki.issn.1000-2200.2020.03.017
[12]	李伊敏 , 程树红 , 张世豪 . IPCL分类对食管早期肿瘤诊断价值的应用. 蚌埠医学院学报, 2019, 44(6): 742-744. doi: 10.13898/j.cnki.issn.1000-2200.2019.06.012
[13]	张万高 , 雷金生 , 张玉梅 . 晚期食管癌食管内支架置入、动脉插管灌注化疗分析. 蚌埠医学院学报, 2006, 31(3): 290-292.
[14]	周慧赟 , 张素琴 , 王磊 , 张雪琴 , 袁牧 . 数字减影血管造影下食管内支架置入术治疗食管癌伴狭窄或食管气管瘘的护理体会. 蚌埠医学院学报, 2015, 40(12): 1742-1744. doi: 10.13898/j.cnki.issn.1000-2200.2015.12.047
[15]	李化龙 , 黄关宏 , 王忠明 . 食管癌的标志物研究进展. 蚌埠医学院学报, 2010, 35(10): 1071-1073.
[16]	刘艳平 , 彭开桂 , 李多杰 . 原发性食管小细胞癌的诊治进展. 蚌埠医学院学报, 2012, 36(11): 1390-1392.
[17]	张凡 , 彭钧 , 李波凌 . p21在食管鳞状细胞癌及食管鳞状上皮良性增生性病变中表达的临床意义. 蚌埠医学院学报, 2010, 35(4): 372-373,376.
[18]	梁书增 , 周谦让 , 程辉 , 杨辉 . 食管切除术后急性胸胃扩张16例临床分析. 蚌埠医学院学报, 2007, 32(2): 160-161.
[19]	崔珍 , 彭开桂 , 沈学明 , 江浩 , 李多杰 , 汪庚明 . Ezrin蛋白在食管鳞癌中的表达及其临床意义. 蚌埠医学院学报, 2009, 34(7): 576-578.
[20]	朱道明 , 乔月华 , 郭方霞 . 内镜下食管贲门癌术后吻合口狭窄扩张治疗. 蚌埠医学院学报, 2009, 34(7): 616-616.

点击查看大图

计量

文章访问数: 3324
HTML全文浏览量: 314
PDF下载量: 481
被引次数: 0

替吉奥联合伽马刀治疗食管癌腹膜后淋巴结转移的临床观察

作者简介: 葛宁(1981-),男,硕士,住院医师.

安徽省肿瘤医院放疗科, 安徽合肥 230031

收稿日期: 2015-06-01

关键词:

摘要: 目的: 探讨替吉奥(S1)联合体部伽马刀治疗食管癌腹膜后淋巴结转移的疗效及不良反应。方法: 回顾性分析69例食管癌腹膜后淋巴结转移患者临床资料, 体部伽马刀治疗时用真空垫和三维立体定向体架固定, 增强CT扫描, 肿瘤靶区外扩10 mm为计划靶区, 50%等剂量线包绕95%计划靶区为处方剂量线, 每次350～450 cGy, 5次/周。10～12次完成。肿瘤边缘总剂量:4 200～4 950 cGy。69例中联合组36例, 行体部伽马刀治疗联合口服S1 40 mg/m²,2次/天, 口服21 d, 28 d为1个周期, 口服4个周期;对照组33例, 单纯行体部伽马刀治疗。结果: 联合组近期总有效率和1年生存率分别为86.11%、77.78%, 对照组分别为63.63%、54.54%, 联合组1年生存率高于对照组(P<0.05)。联合组疼痛缓解总有效率为91.18%, 对照组77.42%, 差异无统计学意义(P>0.05)。2组患者治疗过程中的急性不良反应差异均无统计学意义(P>0.05), 患者均可耐受, 经积极治疗可好转, 未发生治疗相关性病死亡。结论: S1联合体部伽马刀治疗食管癌腹膜后淋巴结转移可提高1年生存率, 不良反应无明显增加。

English Abstract

The clinical observation of the tegafur combined with body gamma knife in the treatment of esophageal neoplasm complicated with retroperitoneal lymph node metastasis

Department of Radiotherapy, Anhui Provincial Cancer Hospital, Hefei Anhui 230031, China

Received Date: 2015-06-01

Abstract: Objective: To evaluate the effects and adverse reactions of the tegafur combined with body gamma knife in the treatment of patients with esophageal neoplasm complicated with retroperitoneal lymph node metastasis.Methods: The clinical data of 69 esophageal neoplasm patients with retroperitoneal lymph node metastases were retrospectively analyzed.Fixing vacuum pad and three-dimensional stereotactic body,enhancing CT scan,enlarging the tumor target area for 10 mm as planning target area,50% dose line embracing 95% planning target area as prescription dose curve and 350 to 450 cGy one time(5 times a week) were implemented at the time of body gamma knife therapy.The treatment was consist of 10 to 12 times,and the total dose of the tumor margin was 4 200-4 950 cGy.Among 69 cases,36 patients(combination group) were treated with the body gamma knife combined with tegafur(40 mg/m²,2 times 1 d,28 days 1 cycle for 4 cycles),33 patients(control group) were only treated with the body gamma knife therapy.Results: The short-term effective rate and 1-year survival rate in the combination group and control group were 86.11% & 77.78% and 63.63% & 54.54%,respectively.The 1-year survival rate in the combination group was higher than that in the control group(P<0.05).The total effective rate of pain relief in the combination group and control group were 91.18% and 77.42%,respectively,the difference of which was not statistically significant(P>0.05).The difference of the acute adverse reaction between two groups was not statistically significant(P>0.05).The patients could tolerate,and were improved after positive treatment.No case died.Conclusions: The treatment of patients with esophageal neoplasm complicated with retroperitoneal lymph node metastasis with tegafur combined with body gamma knife treatment can improve 1-year survival rate,and does not increase the adverse reaction of patients.